Xcout Intel
AbTx
AbTx (Antibody for Therapy) is a preclinical-stage biotechnology company headquartered in Dijon, France. The firm designs personalized medicine biotherapies in oncology based on antibody-drug conjugates (ADCs) to treat incurable cancers.
Subscribe to see AbTx’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AbTx at a glance
AbTx is a biotech company headquartered in France. Its most recent funding round, Seed, raised $1.9M in October 2026. Xcout tracks 1 named person at AbTx, including Meddy El Alaoui (co-founder).
AbTx leadership
- Meddy El Alaouico-founder
AbTx funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $1.9M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent AbTx news
Investors
AbTx competitors
A few of AbTx's closest competitors — see the full list of competitors and alternatives →
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Celyad Oncology is a biopharmaceutical company headquartered in Mont-Saint-Guibert, Belgium, focused on the development of innovative therapies.
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Get AbTx's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on AbTx in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access